Gut microbiota: a potential new territory for drug targeting.
- Published in:
- 2008
- By:
- Publication type:
- research
Works matching IS 14741776 AND DT 2008 AND VI 7 AND IP 2
Results: 23
1
2
Therapeutic area crossroads: anti-angiogenesis.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 115, doi. 10.1038/nrd2507
- By:
- Publication type:
- Article
3
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.
- Published in:
- 2008
- By:
- Publication type:
- Correction Notice
4
Stephen Friend.
- Published in:
- 2008
- Publication type:
- Interview
5
M<sub>3</sub> muscarinic receptors as targets for drug development in neurodegenerative disorders.
- Published in:
- 2008
- By:
- Publication type:
- Letter
6
Derive and conquer: sourcing and differentiating stem cells for therapeutic applications.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 131, doi. 10.1038/nrd2403
- By:
- Publication type:
- Article
7
The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 156, doi. 10.1038/nrd2466
- By:
- Publication type:
- Article
8
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 168, doi. 10.1038/nrd2467
- By:
- Publication type:
- Article
9
Is raising HDL a futile strategy for atheroprotection?
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 143, doi. 10.1038/nrd2489
- By:
- Publication type:
- Article
10
RNA-based therapies.
- Published in:
- 2008
- By:
- Publication type:
- Correction Notice
11
Raltegravir.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 117, doi. 10.1038/nrd2512
- By:
- Publication type:
- Article
12
In this issue.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 103, doi. 10.1038/nrd2528
- Publication type:
- Article
13
The drought continues.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 105, doi. 10.1038/nrd2529
- Publication type:
- Article
14
From industry to academia.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 183, doi. 10.1038/nrd2513
- Publication type:
- Article
15
News & analysis.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 110, doi. 10.1038/nrd2515
- Publication type:
- Article
16
2007 FDA drug approvals: a year of flux.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 107, doi. 10.1038/nrd2514
- By:
- Publication type:
- Article
17
News & analysis.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 112, doi. 10.1038/nrd2516
- By:
- Publication type:
- Article
18
Chemogenomics: A change of tactic.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 122, doi. 10.1038/nrd2521
- By:
- Publication type:
- Article
19
Anticancer drugs: Redesigning kinase inhibitors.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 120, doi. 10.1038/nrd2524
- By:
- Publication type:
- Article
20
High-content screening: Integrating information.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 121, doi. 10.1038/nrd2522
- By:
- Publication type:
- Article
21
Antivirals: Helping hand for HIV.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 120, doi. 10.1038/nrd2523
- By:
- Publication type:
- Article
22
Anticancer drugs: Reversing resistance.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 119, doi. 10.1038/nrd2525
- By:
- Publication type:
- Article
23
in brief.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 2, p. 122, doi. 10.1038/nrd2526
- Publication type:
- Article